Physician profile
Kara Box
NPI 1417426958
$1,185.71
in general payments reported to CMS, 2019-2025
21 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $323 · 2023: $193 · 2024: $18.29 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $668.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $272.65 | 2021-2025 | |
| Abbott Laboratories | $151.05 | 2023 | Proclaim |
| Regeneron Healthcare Solutions, INC. | $91.84 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $72.21 | 2021-2025 | |
| Pfizer INC. | $67.90 | 2021 | |
| Ucb, INC. | $65.79 | 2021-2025 | Bimzelx |
| Genzyme Corporation | $63.20 | 2022-2025 | |
| Abbvie INC. | $60.34 | 2022-2025 | |
| Kerecis Limited | $46.12 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Leo Pharma INC. | $38.18 | 2025 | Spevigo, Anzupgo |
| Ferring Pharmaceuticals INC. | $37.74 | 2025 | Euflexxa |
| Arcutis Biotherapeutics, INC. | $37.55 | 2025 | Zoryve |
| Janssen Biotech, INC. | $31.40 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $23.74 | 2025 | Nuzyra |
| Si-Bone, INC. | $23.65 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.67 | 2025 | Cabtreo |
| Boston Scientific Corporation | $18.29 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.90 | 2023 | Relistor |
| Dermavant Sciences, INC. | $17.45 | 2022 | |
| Incyte Corporation | $15.06 | 2025 | Opzelura |
| Amgen INC. | $14.98 | 2025 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Box listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.